Gut microbiota dysbiosis correlates with a low-dose PCB126-induced dyslipidemia and non-alcoholic fatty liver disease
Gut microbiota dysbiosis correlates with a low-dose PCB126-induced dyslipidemia and non-alcoholic fatty liver disease
复制标题
肠道菌群失调与低剂量 PCB126 诱导的血脂异常和非酒精性脂肪肝相关
DOI：
10.1016/j.scitotenv.2018.10.387
复制
发表时间：
2019-02-25
影响因子：
9.8
通讯作者：
Dong, Sijun
中科院分区：
文献类型：
--
作者：
Chi, Yulang;Lin, Yi;Dong, Sijun
越来越多的证据表明，多氯联苯126（PCB 126）不仅对宿主健康有不利影响，而且还能够改变肠道微生物群，这是最近被认为是决定许多生理过程的关键因素。然而，肠道微生物群与宿主健康之间的相互作用在很大程度上仍然未知。在此，成年雌性C57 BL/6小鼠口服暴露于环境相关的低剂量的PCB 126，50 μ g/kg体重，每周一次，持续6周。本研究旨在阐明PCB 126如何影响肠道菌群变化和宿主疾病，并进一步确定肠道菌群与宿主疾病代谢标志物之间的相关性。获得的结果表明，多氯联苯126给药诱导小鼠肠道微生物群失调，肠道微生物群构成和结构均发生变化。PCB 126管理也同时改变了血清和肝脏的生理状态，如血脂异常，肝脏脂质积累和损伤，非酒精性脂肪肝疾病的评估。重要的是，斯皮尔曼的相关性分析表明，几个特定的细菌类群是积极的和显着相关的代谢标志物所提到的疾病。此外，基于共现网络图，一些细菌分类群可以协同调节宿主生理。这项工作为肠道微生物群与宿主疾病之间相互作用的机制提供了新的见解。预期肠道微生物群调节将是用于预防和治疗PCB 126引发的疾病的另一种新方法。(c)2018 Elsevier B. V.版权所有。
There is growing evidence that polychlorinated biphenyl 126 (PCB126) not only has adverse effects on host health but also has the ability to shift gut microbiota, which is recently recognized as a crucial factor determining numerous physiological processes. However, the interplay between the gut microbiota and host health remains largely unknown. Herein, adult female C57BL/6 mice were orally exposed to environmentally relevant low-dose of PCB126, at 50 mu g/kg body weight once per week for 6 weeks. This study aims to illuminate how PCB126 influences gut microbiota variations and host disorders and to further identify the correlation between the gut microbiota and metabolic markers of host disorders. Obtained results demonstrated that the PCB126 administration induced gut microbiota dysbiosis in mice, with changes both in the gut microbiota constitution and structure. PCB126 administration also simultaneously altered the physiological status of serum and liver, as evaluated by dyslipidemia, liver lipid accumulation and injury, and non-alcoholic fatty liver disease. Importantly, Spearman's correlation analysis suggested that several specific bacterial taxawere positively and significantly related to metabolic markers of the mentioned disorders. Moreover, based on the co-occurrence network map, some of the bacterial taxa may synergistically regulate host physiology. This work provides new insight into the mechanism underlying the interaction between the gut microbiota and host disorders. It is expected that gut microbiota modulation should be another novel way used for the prevention and treatment of PCB126-triggered diseases. (c) 2018 Elsevier B.V. All rights reserved.